ATE416190T1 - Polypeptide mit bindungsaffinität für her2 - Google Patents

Polypeptide mit bindungsaffinität für her2

Info

Publication number
ATE416190T1
ATE416190T1 AT04749087T AT04749087T ATE416190T1 AT E416190 T1 ATE416190 T1 AT E416190T1 AT 04749087 T AT04749087 T AT 04749087T AT 04749087 T AT04749087 T AT 04749087T AT E416190 T1 ATE416190 T1 AT E416190T1
Authority
AT
Austria
Prior art keywords
polypeptide
her2
methods
binding affinity
polypeptides
Prior art date
Application number
AT04749087T
Other languages
English (en)
Inventor
Joergen Carlsson
Stefan Stahl
Tove Eriksson
Elin Gunneriusson
Fredrik Nilsson
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0301987A external-priority patent/SE0301987D0/xx
Priority claimed from SE0400275A external-priority patent/SE0400275D0/xx
Application filed by Affibody Ab filed Critical Affibody Ab
Application granted granted Critical
Publication of ATE416190T1 publication Critical patent/ATE416190T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
AT04749087T 2003-07-04 2004-06-30 Polypeptide mit bindungsaffinität für her2 ATE416190T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301987A SE0301987D0 (sv) 2003-07-04 2003-07-04 New polypeptide
SE0400275A SE0400275D0 (sv) 2004-02-09 2004-02-09 New polypeptide

Publications (1)

Publication Number Publication Date
ATE416190T1 true ATE416190T1 (de) 2008-12-15

Family

ID=33566900

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04749087T ATE416190T1 (de) 2003-07-04 2004-06-30 Polypeptide mit bindungsaffinität für her2

Country Status (10)

Country Link
US (1) US7993650B2 (de)
EP (1) EP1641818B1 (de)
JP (2) JP4871126B2 (de)
AT (1) ATE416190T1 (de)
AU (1) AU2004253835B2 (de)
CA (1) CA2531238C (de)
DE (1) DE602004018141D1 (de)
DK (1) DK1641818T3 (de)
ES (1) ES2319426T3 (de)
WO (1) WO2005003156A1 (de)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200943D0 (sv) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
WO2006092338A2 (en) * 2005-03-01 2006-09-08 Affibody Ab Tnf-alpha binding polypeptide , uses thereof and methods employing it
CN1908015B (zh) * 2005-10-18 2010-09-08 中国人民解放军军事医学科学院基础医学研究所 能抑制her2高表达肿瘤细胞增殖的稳定的小分子多肽
GB0524788D0 (en) 2005-12-05 2006-01-11 Affibody Ab Polypeptides
US7993560B2 (en) 2006-04-20 2011-08-09 Curwood, Inc. Process for introducing an additive into a polymer melt
US7981691B2 (en) 2006-12-08 2011-07-19 General Electric Company Two helix binders
US8198043B2 (en) 2006-12-08 2012-06-12 General Electric Company Two helix binders
US7977118B2 (en) 2006-12-08 2011-07-12 General Electric Company Two helix binders
US7989216B2 (en) 2006-12-08 2011-08-02 General Electric Company Two helix binders
CA2733672C (en) * 2007-08-16 2018-09-11 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
US20100255514A1 (en) 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
US20090148905A1 (en) 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
US9187535B2 (en) * 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2077272A1 (de) 2007-12-21 2009-07-08 Affibody AB Polypeptid-Bibliothek mit vorbestimmtem Gerüst
EP2072525A1 (de) * 2007-12-21 2009-06-24 Affibody AB Neue Polypeptide mit Bindungsaffinität für HER2
EP2271323A2 (de) 2008-05-06 2011-01-12 Glaxo Group Limited Einkapselung biologischer wirkstoffe
AU2009282413B2 (en) 2008-08-11 2014-07-17 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
SG195555A1 (en) * 2008-12-24 2013-12-30 Emd Millipore Corp Caustic stable chromatography ligands
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
EP2401296A1 (de) 2009-02-24 2012-01-04 Glaxo Group Limited Multivalente und/oder multispezifische rankl-bindende konstrukte
WO2010097386A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010120514A2 (en) 2009-03-31 2010-10-21 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
EP2459053A2 (de) 2009-07-28 2012-06-06 F. Hoffmann-La Roche AG Nicht invasives optisches in-vivo-bildgebungsverfahren
EP2496598B1 (de) 2009-11-04 2017-08-02 Affibody AB Her3-bindende polypeptide
TWI377954B (en) * 2009-11-25 2012-12-01 Univ China Medical Oil body carriers, uses in target therapy and/or detection of the same, and fusion proteins comprised therein
PE20170687A1 (es) 2010-01-28 2017-06-13 Glaxo Group Ltd Proteinas de enlace a cd127
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
MX374075B (es) 2010-03-26 2025-03-05 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
CN102939538A (zh) 2010-05-07 2013-02-20 霍夫曼-拉罗奇有限公司 用于离体检测细胞的诊断方法
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
DE102010026061A1 (de) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-markiertes Peptid zur Detektion eines Tumors, der einen Her2/neu-Rezeptor exprimiert
TWI504609B (zh) 2010-11-23 2015-10-21 Glaxo Group Ltd 抗原結合蛋白質
AU2011333738A1 (en) 2010-11-24 2013-07-11 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
JP5974342B2 (ja) * 2010-12-20 2016-08-23 ジーイー・ヘルスケア・バイオプロセス・アールアンドディ・アクチボラグ アフィニティークロマトグラフィーマトリックス
US9061080B2 (en) 2010-12-22 2015-06-23 Ge Healthcare Limited HER2 binding peptides labeled with aluminium-[18] fluoride complexed by NOTA
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
NZ612161A (en) * 2010-12-22 2015-04-24 Gen Electric Radiolabled her2 binding peptides
RU2013128360A (ru) * 2010-12-22 2015-01-27 ДжиИ ХЕЛТКЕР ЛИМИТЕД Her2-связывающие белки, меченые 18f-содержащим кремнийорганическим соединением
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
NZ713461A (en) 2011-04-15 2017-02-24 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
KR101972446B1 (ko) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）­결합 단백질
SG186552A1 (en) 2011-06-08 2013-01-30 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
EP2718326B1 (de) 2011-06-13 2020-08-19 CSL Limited Antikörper gegen g-csfr und verwendungen davon
AU2012327878A1 (en) 2011-10-28 2014-05-29 Patrys Limited PAT-LM1 epitopes and methods for using same
LT2814843T (lt) 2012-02-13 2020-09-25 Agency For Science, Technology And Research ŽMOGAUS MONOKLONINIAI ANTIKŪNAI, NEUTRALIZUOJANTYS IL-1ß
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
EP2831096B1 (de) 2012-03-28 2020-04-29 GE Healthcare BioProcess R&D AB Affinitätschromatografiematrix
JP6285923B2 (ja) 2012-06-22 2018-02-28 トラスティーズ・オブ・ダートマス・カレッジ 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
WO2014013016A1 (en) 2012-07-20 2014-01-23 Affibody Ab Method for determining the her2 status of a malignancy
US9381244B2 (en) 2012-09-07 2016-07-05 King's College London VISTA modulators for diagnosis and treatment of cancer
JP6440618B2 (ja) 2012-10-05 2018-12-19 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
MA38165A1 (fr) 2012-11-08 2018-07-31 Hoffmann La Roche Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
WO2014076179A1 (en) 2012-11-14 2014-05-22 Affibody Ab New polypeptide
JP6146797B2 (ja) * 2013-02-15 2017-06-14 国立大学法人九州大学 Ｈｅｒ２タンパク質検出プローブ、ｈｅｒ２タンパク質検出プローブの製造方法およびｈｅｒ２タンパク質の検出方法
EP3019520B1 (de) * 2013-07-10 2019-12-11 GE Healthcare BioProcess R&D AB Mutierte immunglobulinbindende polypeptide
WO2015051199A2 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
WO2015089585A1 (en) 2013-12-18 2015-06-25 Csl Limited Method of treating wounds
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
ES2809729T3 (es) 2014-03-11 2021-03-05 Molecular Templates Inc Proteínas que comprenden regiones efectoras de la subunidad A de la toxina Shiga próximas al extremo amino terminal y regiones de unión de tipo inmunoglobulina de reconocimiento celular capaces de unirse específicamente a HER2/neu/ErbB2
JP6935195B2 (ja) 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
US11123426B2 (en) 2014-06-11 2021-09-21 The Trustees Of Dartmouth College Use of vista agonists and antagonists to suppress or enhance humoral immunity
EP3173482B1 (de) * 2014-07-09 2020-01-01 Kyoto University Rna-protein-komplex und rna- und proteinabgabesystem damit
CN104130315B (zh) * 2014-07-25 2017-04-05 国家纳米科学中心 一种特异靶向her2蛋白的多肽
BR112017006536A2 (pt) * 2014-09-29 2017-12-19 Fujifilm Corp polipeptídeo de ligação ao anticorpo, polipeptídeo de fusão de ligação ao anticorpo, e material de adsorção
RU2715905C2 (ru) 2014-10-01 2020-03-04 МЕДИММЬЮН, ЭлЭлСи Способ конъюгации полипептида
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
CA2964958A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
EP3224275B1 (de) 2014-11-14 2020-03-04 F.Hoffmann-La Roche Ag Antigenbindende moleküle mit einem ligandentrimer der tnf-familie
CA2969730A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
EP3303373B1 (de) 2015-05-30 2020-04-08 Molecular Templates, Inc. Deimmunisierte shigatoxin-a-untereinheitsgerüste und zellgerichtete moleküle damit
CA2990360C (en) 2015-06-24 2024-02-13 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
KR20180030085A (ko) 2015-07-26 2018-03-21 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
CN105085632B (zh) * 2015-09-14 2019-01-25 国家纳米科学中心 一种特异靶向egfr蛋白的多肽及其应用
CN105085631B (zh) * 2015-09-14 2019-01-25 国家纳米科学中心 一种特异靶向her2蛋白的多肽及其应用
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
WO2017055404A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
US10526413B2 (en) 2015-10-02 2020-01-07 Hoffmann-La Roche Inc. Bispecific antibodies specific for OX40
AU2016334623A1 (en) 2015-10-07 2018-02-15 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory TNF receptor
AU2016361462B2 (en) 2015-11-27 2023-09-21 Csl Limited CD131 binding proteins and uses thereof
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
GB201615588D0 (en) 2016-09-14 2016-10-26 Glaxosmithkline Ip Dev Ltd TSLP Binding Proteins
EP3231813A1 (de) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimere kostimulatorische tnf-familien-ligandenhaltige antigenbindende moleküle
KR20230119259A (ko) 2016-04-15 2023-08-16 이뮤넥스트, 인크. 항-인간 vista 항체 및 이의 용도
WO2017194442A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
EP3243832A1 (de) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und pd1-bindungsteil
JP2020501508A (ja) 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
US20190248920A1 (en) 2016-09-23 2019-08-15 Csl Limited Coagulation factor binding proteins and uses thereof
WO2018083087A2 (en) 2016-11-02 2018-05-11 Glaxosmithkline Intellectual Property (No.2) Limited Binding proteins
WO2018127473A1 (en) 2017-01-03 2018-07-12 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
EP3601346A1 (de) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispezifische antigenbindemoleküle für einen co-stimulierenden tnf-rezeptor
CN110573528B (zh) 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
JP6997209B2 (ja) 2017-04-04 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ４０およびｆａｐに特異的に結合することができる新規な二重特異性抗原結合分子
EP4516809A3 (de) 2017-04-05 2025-09-03 F. Hoffmann-La Roche AG Bispezifische antikörper mit spezifischer bindung an pd1 und lag3
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
EP4512469A3 (de) 2017-09-11 2025-05-21 Monash University Bindung von proteinen an den menschlichen thrombinrezeptor par4
JP7793287B2 (ja) 2017-10-18 2026-01-05 シーエスエル リミティド ヒト血清アルブミン変異体およびその使用
MY205342A (en) 2017-11-01 2024-10-16 Hoffmann La Roche Bispecific 2+1 contorsbodies
JP2021500902A (ja) 2017-11-01 2021-01-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
US20210179721A1 (en) 2017-11-29 2021-06-17 Csl Limited Method of treating or preventing ischemia-reperfusion injury
EP3502140A1 (de) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Kombinationstherapie von tumorabgezielten icos-agonisten mit t-zellenbispezifischen molekülen
SG11202007961QA (en) 2018-04-13 2020-09-29 Hoffmann La Roche Her2-targeting antigen binding molecules comprising 4-1bbl
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
WO2020007817A1 (en) 2018-07-04 2020-01-09 F. Hoffmann-La Roche Ag Novel bispecific agonistic 4-1bb antigen binding molecules
CN109182364A (zh) * 2018-08-30 2019-01-11 武汉百意欣生物技术有限公司 一种特异性识别蛋白a的多克隆抗体及其制备方法和应用
CN112654641A (zh) 2018-10-01 2021-04-13 豪夫迈·罗氏有限公司 具有与cd40的三价结合的双特异性抗原结合分子
WO2020070041A1 (en) 2018-10-01 2020-04-09 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-fap clone 212
UA128001C2 (uk) 2018-12-21 2024-03-06 Ф. Хоффманн-Ля Рош Аг Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули
WO2020127628A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted superagonistic cd28 antigen binding molecules
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
CN110128513B (zh) * 2019-03-22 2023-05-02 温州医科大学 一种对eb病毒lmp2蛋白c端胞膜外区具有结合亲和力的多肽及其应用
JP7301155B2 (ja) 2019-04-12 2023-06-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト リポカリンムテインを含む二重特異性抗原結合分子
KR20220025848A (ko) 2019-06-26 2022-03-03 에프. 호프만-라 로슈 아게 Cea 및 4-1bbl에 결합하는 항체의 융합
WO2020260326A1 (en) 2019-06-27 2020-12-30 F. Hoffmann-La Roche Ag Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
AU2020374942A1 (en) * 2019-11-01 2022-05-26 University Of Houston System Oncolytic virotherapy with induced anti-tumor immunity
WO2021122726A1 (en) * 2019-12-18 2021-06-24 Bracco Imaging Spa Anti-her2 polypeptides derivatives as new diagnostic molecular probes
EP4077368A1 (de) * 2019-12-18 2022-10-26 Bracco Imaging SPA Anti-her2-polypeptidderivate als neue diagnostische molekulare sonden
WO2021119761A1 (en) 2019-12-20 2021-06-24 Hudson Institute of Medical Research Cxcl10 binding proteins and uses thereof
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
CN111592584B (zh) * 2020-05-27 2021-06-29 北京市肿瘤防治研究所 Her2亲和体和诊疗核素标记物及其制备方法与应用
US12583929B2 (en) 2020-06-04 2026-03-24 CSL Innovation Pty Ltd Method of treating acute respiratory distress syndrome
AU2021295549A1 (en) 2020-06-23 2022-11-24 F. Hoffmann-La Roche Ag Agonistic CD28 antigen binding molecules targeting Her2
CN115916830A (zh) 2020-06-25 2023-04-04 豪夫迈·罗氏有限公司 抗cd3/抗cd28双特异性抗原结合分子
KR102350655B1 (ko) * 2020-10-13 2022-01-12 인센 주식회사 테스토스테론-특이적 어피바디 및 이의 용도
CA3195446A1 (en) 2020-10-16 2022-04-21 Amelie Eriksson Karlstrom Pna probes for pretargeted imaging and therapy
CN117916261A (zh) 2020-11-16 2024-04-19 豪夫迈·罗氏有限公司 与靶向fap的cd40激动剂的组合疗法
JP2024503826A (ja) 2021-01-06 2024-01-29 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ１－ｌａｇ３二重特異性抗体及びｃｄ２０ ｔ細胞二重特異性抗体を用いる併用療法
EP4291251B1 (de) 2021-02-15 2025-02-19 Affibody AB Her2-bindendes polypeptid
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
WO2023279092A2 (en) 2021-07-02 2023-01-05 Genentech, Inc. Methods and compositions for treating cancer
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
JP2025511000A (ja) 2022-03-28 2025-04-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト インターフェロンガンマバリアントおよびこれを含む抗原結合分子
US20250325691A1 (en) * 2022-05-18 2025-10-23 Kmd Bio Co., Ltd. Her2-gst-sn-38 complex, and pharmaceutical composition comprising same for preventing or treating proliferative diseases
IL319568A (en) 2022-09-15 2025-05-01 Avidicure Ip B V Multispecific antigen-binding proteins for NK cell stimulation and their uses
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
WO2024188965A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
WO2024246083A1 (en) 2023-06-01 2024-12-05 F. Hoffmann-La Roche Ag Bispecific antibodies targeting bcma and cd28
TW202502811A (zh) 2023-06-01 2025-01-16 瑞士商赫孚孟拉羅股份公司 與ｂｃｍａ特異性結合之免疫刺激性抗原結合分子
IL325176A (en) 2023-07-05 2026-02-01 CSL Innovation Pty Ltd Methods for treating or preventing a complication of sickle cell disease
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
WO2025191139A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of her2-specific antigen binding proteins and cytokines
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
GB9823071D0 (en) 1998-10-21 1998-12-16 Affibody Technology Ab A method
SE9901379D0 (sv) * 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
AU779612C (en) * 1999-07-02 2005-12-15 Genentech Inc. Peptide compounds that bind HER2
JP2003531588A (ja) * 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
GB0017720D0 (en) * 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
CA2881568C (en) * 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b

Also Published As

Publication number Publication date
HK1092481A1 (en) 2007-02-09
JP4871126B2 (ja) 2012-02-08
JP2007537700A (ja) 2007-12-27
DE602004018141D1 (de) 2009-01-15
ES2319426T3 (es) 2009-05-07
US20100048868A1 (en) 2010-02-25
CA2531238A1 (en) 2005-01-13
AU2004253835A1 (en) 2005-01-13
US7993650B2 (en) 2011-08-09
EP1641818A1 (de) 2006-04-05
AU2004253835B2 (en) 2009-01-29
JP2011229531A (ja) 2011-11-17
EP1641818B1 (de) 2008-12-03
JP5689022B2 (ja) 2015-03-25
DK1641818T3 (da) 2009-03-16
CA2531238C (en) 2015-02-24
WO2005003156A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
ATE416190T1 (de) Polypeptide mit bindungsaffinität für her2
SE0400274D0 (sv) New polypeptide
UA97473C2 (ru) Выделенное антитело, которое связывается с her-3, и его применение
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
DE602005016712D1 (de) Rter dna
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
WO2003033654A3 (en) Direct targeting binding proteins
MXPA02012743A (es) Moleculas tipo il-17 y usos de las mismas.
WO2005121331A3 (en) Truncated galnact2 polypeptides and nucleic acids
WO2004024750A3 (en) Cd44-binding ligands
ATE522541T1 (de) Bakterielle adhäsine konformere
WO2005097185A3 (en) Irta-5 antibodies and their uses
WO2007018619A3 (en) Chimeric therapeutic agents
DE60041243D1 (de) Gebrauchsverfaheren eines neuen lysyloxidase-verwandten proteins
WO2020185796A9 (en) High avidity wt1 t cell receptors and uses thereof
WO2003065003A3 (en) Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
MX2025010859A (es) Polipéptidos de fusión dap10/dap12.
SE0301987D0 (sv) New polypeptide
ATE490268T1 (de) Tnf-alhpa-bindendes polypeptid, anwendungen davon und verfahren, bei denen dieses verwendet wird
AU1959001A (en) Histone deacetylase-8 proteins, nucleic acids, and methods of use
EP1576157A4 (de) Fluoreszenzproteine aus copepoda-speziesund verfahren zur verwendung davon
BR0317161A (pt) Moléculas de ligação nogo a e uso farmacêutico das mesmas
TNSN06085A1 (en) Nogo-a binding with enhanced affinity and pharmaceutical use thereof
PL374550A1 (en) Il-17 like molecules and uses thereof
WO2001042285A3 (en) Extracellular matrix and cell adhesion proteins as well as genes encoding them

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties